Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...
Scientists have developed retriever, a computational tool that extracts disease-specific drug response signatures to predict the best combinations for cancer treatment.
Spending years in a biochemistry lab studying tRNA while enduring the social isolation of the pandemic isn’t exactly where most Fidelity employees got their start. It is the case, however, for ...